Listen
Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the new indication of treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk of fracture.
-
Clinical Benefit
| Substantial |
The actual benefit of this proprietary drug is substantial. |
Clinical Added Value
| minor |
In view of the available data, the Committee considers that FORSTEO will provide a minor improvement in actual benefit (IAB IV) in the treatment of glucocorticoid-induced osteoporosis in women and men at high risk of fracture with at least two vertebral fractures. |
Contact Us
Évaluation des médicaments
